Inventor
JACOBSEN ERIC JON
US43 patents
⚠️ This page may combine multiple inventors who share the name “JACOBSEN ERIC JON”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
UPJOHN CO
15 patentsUS6500840B2Dec 31, 2002
Quinuclidine-substituted heteroaryl moieties for treatment of disease
UPJOHN CO66 citations95
US6492385B2Dec 10, 2002
Quinuclidine-substituted heteroaryl moieties for treatment of disease
UPJOHN CO70 citations95
US6407092B1Jun 18, 2002
Tetracyclic azepinoindole compounds
UPJOHN CO110 citations95
US5804593ASep 8, 1998
α-Amino sulfonyl hydroxamic acids as matrix metalloproteinase inhibitors
UPJOHN CO71 citations94
US6599916B2Jul 29, 2003
Quinuclidine-substituted heteroaryl moieties for treatment of disease
UPJOHN CO53 citations92
US6562816B2May 13, 2003
Substituted-heteroaryl-7-aza[2.2.1]bicycloheptanes for the treatment of disease
UPJOHN CO26 citations92
US6894042B2May 17, 2005
Azabicyclic compounds for the treatment of disease
UPJOHN CO12 citations84
US6579870B2Jun 17, 2003
Bis-arylsulfones
UPJOHN CO8 citations73
US6586421B2Jul 1, 2003
Substituted azepino[4,5b]indoline derivatives
UPJOHN CO5 citations72
US6468999B1Oct 22, 2002
1,2,3,4,5,6,-hexahydroazepino [4,5-b]indoles containing arylsulfones at the 9-position
UPJOHN CO6 citations66
US5859061AJan 12, 1999
Bis-sulfonamides hydroxamic acids as MMP inhibitors
UPJOHN CO3 citations62
US6583135B2Jun 24, 2003
Substituted azepino[4,5b]indole derivatives
UPJOHN CO1 citations60
US6586592B2Jul 1, 2003
Bis-arylsulfones
UPJOHN CO0 citations47
US6878823B2Apr 12, 2005
1,2,3,4,5,6-hexahydroazepino[4,5-b]indoles containing arylsulfones at the 9-position
UPJOHN CO0 citations44
US7030109B2Apr 18, 2006
1,2,3,4,5,6-Hexahydroazepino[4,5-b]indoles containing arylsulfones at the 9-position
UPJOHN CO0 citations35
PFIZER
13 patentsUS7001900B2Feb 21, 2006
Azabicyclic compounds for the treatment of disease
PFIZER74 citations97
US6911543B2Jun 28, 2005
Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease
PFIZER71 citations96
US6919359B2Jul 19, 2005
Azabicyclic-substituted-heteroaryl compounds for the treatment of disease
PFIZER61 citations95
US6828314B2Dec 7, 2004
Substituted azepino[4,5b]indoline derivatives
PFIZER38 citations95
US6849620B2Feb 1, 2005
N-(azabicyclo moieties)-substituted hetero-bicyclic aromatic compounds for the treatment of disease
PFIZER48 citations91
US6951868B2Oct 4, 2005
Azabicyclic-phenyl-fused-heterocyclic compounds for treatment of disease
PFIZER14 citations84
US6875762B2Apr 5, 2005
Tetracyclic azepinoindole compounds
PFIZER15 citations82
US7176198B2Feb 13, 2007
1H-pyrazole and 1H-pyrrole-azabicyclic compounds for the treatment of disease
PFIZER9 citations73
US6903090B2Jun 7, 2005
Substituted azepino[4,5b]indole derivatives
PFIZER5 citations72
US6858613B2Feb 22, 2005
Fused bicyclic-N-bridged-heteroaromatic carboxamides for the treatment of disease
PFIZER5 citations62
US6852716B2Feb 8, 2005
Substituted-aryl compounds for treatment of disease
PFIZER6 citations62
US8372854B2Feb 12, 2013
Pyrrolo[2,3-D]pyrimidine compounds
PFIZER3 citations60
US6869946B2Mar 22, 2005
Substituted azabicyclic moieties for the treatment of disease
PFIZER0 citations52
ACLARIS THERAPEUTICS INC
10 patentsUS11739086B2Aug 29, 2023
Substituted pyrrolopyridine JAK inhibitors and methods of making and using the same
ACLARIS THERAPEUTICS INC4 citations84
US10981906B2Apr 20, 2021
Substituted pyrrolopyridine JAK inhibitors and methods of making and using the same
ACLARIS THERAPEUTICS INC9 citations84
US10800775B2Oct 13, 2020
Pyrazolyl pyrrolo[2,3-b]pyrmidine-5-carboxylate analogs and methods of making the same
ACLARIS THERAPEUTICS INC8 citations83
US12281111B2Apr 22, 2025
Substituted pyrrolopyridine JAK inhibitors and methods of making and using the same
ACLARIS THERAPEUTICS INC1 citations73
US11820775B2Nov 21, 2023
Pyrrolopyrimidine ITK inhibitors
ACLARIS THERAPEUTICS INC2 citations70
US11021482B2Jun 1, 2021
Pyrrolopyrimidine ITK inhibitors
ACLARIS THERAPEUTICS INC2 citations70
US12297203B2May 13, 2025
Pyrrolopyrimidine ITK inhibitors
ACLARIS THERAPEUTICS INC0 citations59
US10150783B2Dec 11, 2018
Heterocyclic ITK inhibitors for treating inflammation and cancer
ACLARIS THERAPEUTICS INC0 citations51
US11420966B2Aug 23, 2022
Substituted pyrrolopyridines as JAK inhibitors
ACLARIS THERAPEUTICS INC0 citations46
US10316038B2Jun 11, 2019
Pyrrolopyrimidine ITK inhibitors for treating inflammation and cancer
ACLARIS THERAPEUTICS INC0 citations40
CONFLUENCE LIFE SCIENCES INC
3 patentsUS9695200B2Jul 4, 2017
Heterocyclic ITK inhibitors for treating inflammation and cancer
CONFLUENCE LIFE SCIENCES INC19 citations91
US9499551B2Nov 22, 2016
Substituted pyrrolo[2,3-b]pyridines for treating cancer or inflammatory diseases
CONFLUENCE LIFE SCIENCES INC4 citations71
US9145393B2Sep 29, 2015
Arylpyridinone ITK inhibitors for treating inflammation and cancer
CONFLUENCE LIFE SCIENCES INC2 citations62